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Sunitinib, a multitargeted tyrosine-kinase inhibitor, extends survival of patients with metastatic renal cell carcinoma (mRCC) and
gastrointestinal stromal tumours. Between October 2005 and March 2007, we retrospectively reviewed blood glucose level
variations associated with sunitinib therapy in patients treated for mRCC. Nineteen of the patients had type II diabetes. All 19 patients
had a decrease in blood glucose level (mean 1.77mmoll
 1) after 4 weeks of treatment. This was followed by re-elevation in the
2-week rest period. After two cycles of sunitinib administration, two patients had stopped blood glucose-lowering drugs whereas five
other patients had normalised their blood glucose level. On the basis of pre-clinical data, we hypothesise that several mechanisms
could be involved in this process, such as capillary regression of pancreatic islets, IGF-1 modulation through HIF1-a or NF-kB
activation. In addition, a decrease of glucose uptake in the context of concomitant gastrointestinal toxicity cannot be excluded.
Glycaemic control should be carefully evaluated in diabetic patients treated with sunitinib, and routine monitoring is warranted.
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Sunitinib (sunitinib malate; SU11248; SUTENT
s; Pfizer Inc., New
York, NY, USA) is an orally bioavailable, oxindole, multi-targeted
tyrosine kinase inhibitor with antitumour and antiangiogenic
activities. Sunitinib has been identified in both biochemical and
cellular assays (Faivre et al, 2007) as a potent inhibitor of VEGFRs
(types 1–3), PDGFR (a and b), as well as FLT3, Kit (stem-cell
factor (SCF) receptor), colony-stimulating factor type I (CSF-1R)
and glial cell-line-derived neurotrophic factor receptor (RET).
Antitumour activity in metastatic renal clear cell carcinoma
(mRCC) has been demonstrated in phase II (Motzer et al, 2006)
and in phase III studies (Motzer et al, 2007). In the international
randomised phase III trial (Motzer et al, 2007), the efficacy and
safety of sunitinib as compared with IFN-a in first-line treatment
of patients with mRCC were evaluated. Median progression-free
survival was 11 months (95% CI: 8.14) for sunitinib vs 5 months
for IFN-a (95% CI: 4.6), corresponding to a hazard ratio of 0.42
(95% CI: 0.32–0.54) (Po0.001). The objective response rate, by a
third-party independent review was 31% for sunitinib vs 6% for
the IFN-a (Po0.001). In all, 632 patients (85%) are alive, with 49
deaths on the sunitinib arm and 65 deaths on the IFN-a arm. On
the basis of this large phase III study, sunitinib became one of the
standard therapies for the first-line treatment of mRCC.
The main toxicities reported in the phase II and III trials with
sunitinib were fatigue, hand/foot syndrome, intestinal toxicity
(including mucositis and diarrhoea) and hypertension. Eight
percent withdrew from the phase III study due to adverse events
on the sunitinib arm vs 13% on the IFN-a arm (Motzer et al, 2007).
In addition to the side effects described in these publications,
atypical toxicities, such as hypothyroidism (Rini et al, 2007) or
vitamin deficiencies (Gillessen et al, 2007) have been reported.
Recently, Templeton et al (2008) reported an interesting clinical
case of remission of type I diabetes after sunitinib treatment. In
this report, we describe our investigation of blood glucose level
variations in a large cohort of patients treated with sunitinib.
PATIENTS AND METHODS
Between October 2005 and March 2007, 200 patients with mRCC,
included in the phase III study or in an expanded access
programme, have been followed at the Pitie-Salpetriere and
George-Pompidou hospitals. All patients signed a written informed
consent form that was approved by external review boards and
were treated with sunitinib at the initial dose of 50mg daily (50mg
given daily, 4 weeks on, 2 weeks off). The medical records of
patients with mRCC treated in our institutions with sunitinib were
retrospectively reviewed for glucose blood level alterations and use
of blood glucose-lowering drugs. The main inclusion criteria for
this retrospective study were age 18 or older, histologically or
cytologically confirmed mRCC, adequate hepatic, renal and bone
marrow function, and repeated fasting glucose blood analysis at
baseline and on days 1 and 28 of each cycle. All patients with type I
or 2 diabetes, defined as case patients, were compared with control
patients with mRCC. Control patients were defined consistently
normoglycaemic at baseline and during sunitinib treatment. The
longitudinal analysis of blood glucose level variation was
performed with the non-parametric Wilcoxon test. Patients were
considered as their own control in paired analysis.
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In our analysis, 19 patients had type II diabetes. Five patients out
of 19 had pancreatic metastases. The mean baseline blood glucose
level for all 19 was 8.26mmoll
 1 (range 4.05–13.80). These 19
patients were treated with oral antihyperglycaemic medications
including metformin, glibenclamide and gliclazide. Two patients
were insulin dependent. The demographic characteristics of
patients treated are presented in Table 1.
After 4 weeks of treatment, all 19 patients had a decrease of
blood glucose level (mean 1.77mmoll
 1; P¼0.05), and this was
followed by an increase of blood glucose level during the rest
period (mean 0.93mmoll
 1) (Figure 1). After two cycles of
sunitinib (12 weeks), two patients were able to stop their
antihyperglycaemic treatment during the treatment phase and
reinitiated their medication during the sunitinib rest period. Five
other patients have normalised their blood glucose level. No severe
episode of hypoglycaemia has been reported.
By comparison, blood glucose level from nine non-diabetic
‘control’ patients (Figure 1) were analysed, and a nonsignificant
decrease of mean level was observed from 5.89 to 5.26mmoll
 1
(P¼0.79). The trend over the time of blood glucose levels seems to
be different for non-diabetic patients with no variation during
sunitinib therapy or in the 2 weeks off treatment. In a global
analysis of all 28 patients treated with 4 weeks of sunitinib, the
blood glucose level decreased from 7.59 to 6.03mmoll
 1
(P¼0.04).
DISCUSSION
Type II diabetes mellitus is an extremely complex disorder
involving insulin resistance and b-cell dysfunction. Insulin
receptors and IG1 receptors activate a number of post-receptor
cascades including Irs, Sgk or Akt-2 protein kinases inducing
protein synthesis, antilipolysis and cell survival (Leroith and
Accili, 2008). The exact mechanism involved in our observation
remains to be elucidated but several hypotheses can be elaborated.
First, Kamba et al (2006) have reported similar observations in
mice models using AG-013736, which is also a tyrosine kinase
inhibitor of VEGFR-1, -2 and -3. In this animal model, a 21-day
pre-treatment with AG-013736 improved blood glucose handling.
According to the authors, this phenomenon could be partially
related to significant quantitative and qualitative capillary regres-
sion in pancreatic islets. Interestingly, this VEGF-dependant
phenomenon was reversible after cessation of the treatment.
Second, IGF-1 regulates VEGF expression through HIF1-a (Carroll
and Ashcroft, 2006). We could hypothesise that sunitinib
treatment could interfere with the IGF-1 pathway, having a
subsequent impact on insulin resistance. To investigate this
hypothesis, IGF-1 serum levels were monitored in five patients
in our diabetic cohort. Although a decrease was observed at week
4, this was not significant (data not shown, P¼0.06). Third,
amelioration of diabetes by imatinib (Gleevec
s) has been reported
in animal models (Hagerkvist et al, 2007) and in human (Veneri
et al, 2005). This unexpected effect was related to the protective
effect of imatinib on b cells by an antiapoptotic action through
NF-kB activation. However, an effect of sunitinib on NF-kB
modulation has yet not been reported. Modulation of the IGF
pathway has also been implicated in exacerbation of hypo-
glycaemia by imatinib in patients with non-islet-cell tumours
(Hamberg et al, 2006).
A decrease of glucose uptake in a context of concomitant
gastrointestinal toxicity cannot be excluded. Anorexia and
Table 1 Baseline characteristics of the 28 patients with metastatic renal
cell carcinoma
Characteristics
Type 2 diabetic
N¼19
Non-diabetic
N¼9
Sex
Male/female 18/1 8/1
Age (years)
Mean (range) 62 (52–74) 57 (42–77)
PS p11 8 8
Diagnostic age
Mean (range) 61 (47–65) 53.7 (39–73)
Metastatic age
Mean (range) 61 (50–72) 56 (42–77)
Histology
Clear cell 19 8
Chromophobe 0 1
Nephrectomy 19 7
Primary tumour 0 2
Pre-treatment
p2 lines 10 4
INF 16 9
IL-2 1 2
INF+IL-2 2 0
Hormonotherapy 2 1
Radiotherapy 2 1
Antiangiogenic agents 8 9
Chemotherapy 2 1
Metastasis site
Liver 5 5
Lung 16 7
Pancreas 5 1
42 sites 10 4
Diabetes treatment
Insulin 2 0
Metformin 4 0
Glibenclamide 0 0
Glicazide 10 0
Repaglinide 1 0
Benfluorex 1 0
Biguanide+glitazone 1 0
Pioglitazone 1 0
IGF-1 5 patients —
Baseline, median–mean (range) 56.4–59.3 (46.3–82.4) —
Week 4, median–mean (range) 62–119.5 (29–64.1) —
IGF-1¼insulin growth factor; IL-2¼interleukin-2; INF¼interferon.
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P = 0.05 
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Figure 1 Mean blood glucose levels in 19 type II diabetic patients and
9 non-diabetic patients during sunitinib treatment for mRCC.
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sintestinal toxicity (Motzer et al, 2007) have been reported in the
phase III study and oral glucose uptake could consequently be
reduced. In addition, direct intestinal toxicity of sunitinib has been
reported, and this could induce vitamin malabsorption (Gillessen
et al, 2007). However, the hypothesis of altered glucose transport is
not confirmed, as glucose handling was not modified in the animal
model after an intravenous compared with an oral glucose
challenge after AG-013736 treatment (Kamba et al, 2006). Finally,
drug–drug interaction (between sunitinib and blood glucose-
lowering drugs) could be advanced as an additional basis for our
findings. A pharmacokinetic analysis to explore the relationship
between sunitinib and blood sugar levels deserves further
investigation.
Our data suggest that sunitinib lowers the blood glucose level.
The indications for and the dose of blood glucose-lowering drugs
should be evaluated during both the active treatment period and
the rest period. To avoid severe hypoglycaemia, oral blood
glucose-lowering drugs should be carefully monitored in this
context. A potential relationship with sunitinib efficacy should be
addressed in a large prospective analysis.
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